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The formation of the vascular system is essential
for embryonic development and homeostasis. How-
ever, transcriptional control of this process is not
fully understood. Here we report an evolutionarily
conserved role for the transcription factor CASZ1
(CASTOR) in blood vessel assembly and morpho-
genesis. In the absence of CASZ1, Xenopus embryos
fail to develop a branched and lumenized vascular
system, and CASZ1-depleted human endothelial
cells display dramatic alterations in adhesion, mor-
phology, and sprouting. Mechanistically, we show
that CASZ1 directly regulates Epidermal Growth
Factor-Like Domain 7 (Egfl7). We further demon-
strate that defects of CASZ1- or EGFL7-depleted
cells are in part due to diminished RhoA expres-
sion and impaired focal adhesion localization. More-
over, these abnormal endothelial cell behaviors in
CASZ1-depleted cells can be rescued by restoration
of Egfl7. Collectively, these studies show that CASZ1
is required to directly regulate an EGFL7/RhoA-
mediated pathway to promote vertebrate vascular
development.
INTRODUCTION
Endothelial cells (ECs) are building blocks for the formation of a
functional vascular systemduring embryonic development. Early
stages of blood vessel development occur via vasculogenesis,
whereby mesodermal cells differentiate into EC progenitors
that subsequently proliferate, migrate, and assemble into vas-
cular cords. The cords then undergo tubulogenesis, or lumen
formation, and continue to mature by angiogenesis, whereby
vessels sprout, branch, and remodel. The vessels then become
surrounded and stabilized by pericytes and smooth muscle cells
that provide structural support (De Val, 2011; Patan, 2000). The132 Developmental Cell 25, 132–143, April 29, 2013 ª2013 Elsevier Icritical nature of these events is emphasized by observations
that disruption of these processes is associated with human dis-
ease states, including cancer, stroke, and atherosclerosis, high-
lighting the need for a better understanding of the transcriptional
networks that regulate these key developmental steps (Carme-
liet, 2003; Carmeliet and Jain, 2011; Potente et al., 2011).
Although numerous transcription factors have been dis-
covered to regulate endothelial gene expression, relatively few
factors are necessary for development. Deletions or mutations
of a number of single genes, especially members of the Ets
and forkhead families, result in moderate to no vascular pheno-
types, likely due to functional redundancy (Barton et al., 1998;
De Val, 2011; De Val and Black, 2009; Lelie`vre et al., 2001). Pre-
vious studies have implicated the zinc finger transcription factor
CASZ1 (CASTOR) in cardiovascular development, with depletion
of CASZ1 in Xenopus embryos resulting in the failure of a subset
of progenitor cells to differentiate into cardiomyocytes (Christine
and Conlon, 2008). Recent genome-wide association studies
have shown a genetic link between humanCasz1 and high blood
pressure and hypertension, suggesting a possible role for
CASZ1 in EC biology (Levy et al., 2009; Takeuchi et al., 2010).
However, no studies have addressed the expression, function,
or transcriptional targets of CASZ1 in vascular tissue.
Despite an essential role of the vasculature in development
and disease, our knowledge about the molecular mechanisms
that control these events remains incomplete (De Val and Black,
2009). One protein that was recently shown to play a role in EC
morphogenesis is Epidermal Growth Factor-Like Domain 7
(Egfl7), an extracellular matrix (ECM) protein that is expressed
exclusively in EC progenitors and vessels during embryonic
and neonatal development. EGFL7 is also expressed in highly
vascularized adult organs and is upregulated upon injury
(Campagnolo et al., 2005; Fitch et al., 2004; Parker et al.,
2004). Depletion studies in zebrafish have defined a role for
EGFL7 in tubulogenesis, likely through modulation of cell-matrix
interactions (Nikolic et al., 2010; Parker et al., 2004). In addition,
overexpression of Egfl7 in mouse results in abnormal patterning
of embryonic and postnatal vasculature (Nichol et al., 2010).
However, efforts to identify the specific function of EGFL7
have been complicated by the recent discovery of microRNAnc.
Figure 1. CASZ1 Expression in Vascular ECs Is Evolutionarily
Conserved
(A) In situ analysis of Casz1 Xenopus embryos (stage 41; lateral view with
anterior to the left). Casz1 is expressed in vascular structures, including the
vitelline vein network (vvn; enlarged panel on the right).
(B) CASZ1 (green) colocalizes with PECAM (red) in neural blood vessels of
E14.5 mouse embryos.
(C) RT-PCR analysis of human Casz1 in HUVEC cDNA. Gapdh was used as
loading control.
(D) IP of CASZ1 from HUVECs. Control lane (left) represents IP with no anti-
body (Ab). Arrowhead represents 125 kD human CASZ1. See also Figure S1.
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CASZ1 Directly Regulates EGFL7/RhoAmiR-126, the only EC-specific microRNA, within intron 7 of the
Egfl7 locus. Although Egfl7 and miR-126 are coexpressed,
miR-126 plays a role distinct from that of its host gene in main-
taining vessel integrity and modulating angiogenesis through
repression of the targets Spred1 and PIK3R2 (Fish et al., 2008;
Kuhnert et al., 2008; Wang et al., 2008).
In this study, we demonstrate that CASZ1 is required for
angiogenic sprouting and lumen morphogenesis. CASZ1
regulates EC contractility, adhesion, and sprouting, thereby pro-
moting the assembly and tubulogenesis of blood vessels.
Furthermore, we demonstrate that CASZ1 activates Egfl7 in
mammals and Xenopus by binding directly to an intronic
element. However, CASZ1 regulates miR-126 in mammals but
not in Xenopus. Moreover, defects associated with CASZ1
depletion can be phenocopied by EGFL7 depletion and, impor-
tantly, rescued by restoration of Egfl7 levels. We further show
CASZ1 transcriptional control of EGFL7 modulates EC behavior
through RhoA. Collectively, our studies point to a network
whereby CASZ1 regulates an EGFL7/RhoA-mediated pathway
to promote vessel assembly and morphogenesis.
RESULTS
EC Expression of CASZ1 Is Evolutionarily Conserved
Analysis of Casz1 expression in Xenopus embryos showed
transcripts in the vitelline vein network at a stage when the
network is primarily made up of vascular ECs and devoid of
smooth muscle cells (Figure 1A; Christine and Conlon, 2008;
Cox et al., 2006; Warkman et al., 2005), suggesting that Casz1
is expressed in vascular ECs. Furthermore, RT-PCR on vascular
explants from late-tailbud-stage embryos (stage 32) demon-
strated that Casz1 is coexpressed in the vitelline vein region
with the vascular markers Msr and Erg (Figure S1A available
online). Consistently, we found that CASZ1 colocalizes with the
EC-specific marker PECAM in blood vessels of mouse embryos
(Figure 1B). We went on to clone human Casz1 and showed that
Casz1 is expressed in primary human umbilical vein ECs
(HUVECs; Figures 1C and 1D). Together with the previously re-
ported sequence homology and synteny of CASZ1 across verte-
brates (Christine and Conlon, 2008), these results demonstrate
that CASZ1 is an evolutionarily conserved transcription factor
expressed in ECs.
CASZ1 Is Required for Vascular Patterning and Lumen
Morphogenesis
To ascertain the function of CASZ1 in vascular development, we
depleted CASZ1 in Xenopus embryos using a morpholino (MO)-
based approach (Christine and Conlon, 2008). Whole-mount
in situ hybridization using a panel of EC markers such as Msr
and Erg (Baltzinger et al., 1999; Devic et al., 1996) demonstrated
that at stages when ECs began to migrate dorsally from ventral
blood islands within the trunk region, there were no noticeable
differences between control and CASZ1-depleted embryos
(stage 29; Figures S1B, S1C, S1J, and S1K). However, when
ECs began to assemble into cords (stage 32), defects became
apparent (e.g., CASZ1-depleted embryos displayed a dramati-
cally reduced vascular plexus; Figures 2A–2D, S1D, and S1E).
Extension of intersomitic vessels from posterior cardinal veins,
which is known to occur in Xenopus via sprouting angiogenesisDevein an anterior-to-posterior direction (Cleaver et al., 1997; Levine
et al., 2003), was also absent or significantly delayed in
CASZ1-depleted embryos (Figures 2A, 2C, 2E, and 2G). By the
mid- to late-tadpole stages (stages 36 and 39, respectively),
the vascular networks of CASZ1-depleted embryos were com-
prised of cords that ran predominantly in a dorsal-to-ventral
pattern and underwent little to no branching or remodeling (Fig-
ures 2E–2H, S1F–S1I, S1L, and S1M). Overall, at stage 36, the
total length of the vitelline vein vasculature and the number of
branch points and intersomitic vessels were all significantly
decreased in CASZ1-depleted embryos (Figure 2I). While our
studies focused on vein-derived sprouts, CASZ1 is unlikely to
be required for arterial/venous specification based on observa-
tions that the aortic arches (arterial) and posterior cardinal veins
are properly specified and positioned in CASZ-depleted
embryos, and expression of arterial markers is absent in veins
(data not shown). Collectively, these data imply a role for
CASZ1 in sprouting and remodeling of the vasculature.
Noting that the posterior cardinal veins of CASZ1-depleted
embryos appeared thickened (stage 36), we sought to determine
the time course of lumen formation in Xenopus. At stage 29, con-
trol and CASZ1-depleted ECs, as marked byMsr, were localized
to positions of the future veins but had not yet undergone lumenlopmental Cell 25, 132–143, April 29, 2013 ª2013 Elsevier Inc. 133
Figure 2. CASZ1 Is Required for Vascular
Development and Lumen Formation
(A–H) In situ analysis with EC marker Msr of
control and CASZ1-depleted embryos (stages
32–36; lateral view with anterior to the left).
Vessel patterning and branching within the vvn
are severely compromised at stage 32 in CASZ1-
depleted embryos (A and C: high magnification
of the vvn in B and D) and stage 36 (E and G:
high magnification of the vvn in F and H).
Note the poor sprouting of intersomitic vessels
(isv) in CASZ1-depleted embryos at both
stages (enlarged box in A, C, E, and G). n =
10 embryos/condition/stage, three independent
experiments. pcv, posterior cardinal vein.
(I) Quantification of vascular defects in control
and CASZ1-depleted embryos (stage 36) repre-
senting the combined total length of vessels,
number of branch points within the vvn, and
number of isv/embryo, respectively. Data
represent mean ± SEM (n = 7 control and
10 Casz1 MO embryos). *p < 0.05, **p < 0.01,
***p < 0.001.
(J–Q) Histological analysis illustrates the time
course of lumen formation in Xenopus from
stage 29 to stage 39 (J–M). Note that posterior
cardinal vein (pcv) lumens begin to open between
stages 32 and 36 in control embryos (K and L) but
fail to form in CASZ1-depleted embryos (N–Q).
Dorsal is top, ventral is bottom. Arrowheads
correspond to positions of pcv that are enlarged
in lower panels (n = 2–5 embryos/condition/
stage).
See also Figure S1.
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CASZ1 Directly Regulates EGFL7/RhoAformation (Figures 2J and 2N). By stage 32, the ECs separated
in control embryos but remained as aggregates in CASZ1-
depleted embryos (Figures 2K and 2O). By stages 36 and 39,
the veins of control embryos exhibited well-formed lumens sur-
rounded by Msr-positive ECs, whereas the CASZ1-depleted
veins remained closed and failed to open even at late stages
(Figures 2L, 2M, 2P, and 2Q). Collectively, these studies demon-
strate that CASZ1 is required for angiogenic remodeling and
lumen morphogenesis during vertebrate vascular development.
Because we previously established that CASZ1 is required for
heart development (Christine and Conlon, 2008), we sought to
determine whether the vascular requirements for CASZ1 are
secondary to its role in cardiac tissue. Taking advantage of the
amenability of Xenopus embryos to organotypic culture (Mandel
et al., 2010), we removed anterior regions of embryos, including
all cardiac tissue at a stage prior to heart formation. Culture of
explants showed that in the absence of cardiac tissue, the
control explants formed vascular networks, as marked by the
EC-specific gene Ami (Inui and Asashima, 2006), that were indis-
tinguishable from those of unmanipulated embryos, demon-
strating that blood flow is not essential for correct patterning of134 Developmental Cell 25, 132–143, April 29, 2013 ª2013 Elsevier Inc.the early vasculature (Figures S1N and
S1P). Critically, we observed severe
defects in the vascular networks of
CASZ1-depleted explants, strongly sug-
gesting that the role of CASZ1 in vasculardevelopment is independent of its role in cardiogenesis (Figures
S1O and S1Q).
CASZ1 Regulates EC Behavior
To examine vascular development in more detail and determine
whether the function of CASZ1 is evolutionarily conserved, we
depleted CASZ1 in HUVECs by lentiviral-mediated short hairpin
RNA (shRNA, a 16-fold decrease in Casz1 messenger RNA
[mRNA]; Figure 3A). CASZ1-depleted cells displayed a thin and
elongated morphology in stark contrast to the characteristic
cobblestone appearance of uninfected HUVECs or HUVECs in-
fected with control shRNA (Figure 3B).
To determine the precise requirement for CASZ1 and to
characterize the dynamics of CASZ1-depleted HUVECs in real
time, we coupled time-lapse imaging with quantitative analysis.
Time-lapse movies showed that CASZ1-depleted cells initially
adhered to plastic or fibronectin-coated substrates, but a pro-
portion of the cells rounded up and detached (33%; Figure 3C;
Movie S1; data not shown). In the CASZ1-depleted HUVECs
that adhered, live imaging demonstrated that the elongated
morphology resulted from defects in contractility whereby the
Figure 3. CASZ1 Regulates EC Behavior
(A) mRNA levels of Casz1 after infection of
HUVECs with shCasz1. Casz1 is decreased by
16-fold. mRNA levels relative to Rps29 ± SEM.
***p < 0.001.
(B) Phase-contrast images of control and shCasz1
HUVECs. Controls display cobblestone-like mor-
phology, whereas CASZ1-depleted cells are thin
and elongated (red arrowheads indicate examples
of each).
(C) Time-lapse images of control and shCasz1
cells. Red arrowheads indicate dividing control
cells and rounded-up CASZ1-depleted cells.
Bottom right: Minutes elapsed, taken every 5 min
for 24 hr. Red arrow points to an elongated
shCasz1 cell with trailing edge defects. Graph
represents quantification of cells that round up
and detach during imaging. Data represent the
mean ± SEM of three experiments conducted
on independent batches of shRNA-infected cells
(n = 200 cells). **p < 0.01.
(D) A sprouting angiogenesis assay was per-
formed with control and CASZ1-depleted
HUVECs. On day 6, cultures were fixed and
stained for phalloidin (green) and DRAQ5 (blue).
Graphs represent the mean ± SEM of total sprout
length and number of branch points/bead (n = 11
beads/condition). Experiments were repeated
twice on independent batches of shRNA-infected
cells. **p < 0.01, ***p < 0.001.
See also Figure S2 and Movies S1 and S4.
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retraction of the trailing edge (Figure 3C; Movie S1). CASZ1-
depleted cells also stopped dividing (0% shCasz1 versus 20%
control) and we consistently failed to detect any phospho-
Histone H3 (pH3)-positive CASZ1-depleted cells (versus 3%
control cells; Figure S2A). Using fluorescence-activated cell
sorting (FACS), we determined that CASZ1-depleted ECs were
blocked at the G1/S transition as seen by the significantly
reduced number of cells in S phase (Figure S2B). Blockage in
G1/S progression was not associated with programmed cell
death asdeterminedby cleaved caspase-3 staining (Figure S2C).
Furthermore, the inability of CASZ1-depleted cells to maintain
adhesion to the substrate was not a secondary consequence
of cell-cycle arrest, as wild-type HUVECs that were chemically
treated with mitomycin C did not divide yet remained attached
(data not shown). Taken together, these results indicate that
CASZ1 has a conserved role in vascular development and is
required for EC adhesion, contractility, and G1/S cell-cycle
progression.
To assess how adhesive and morphological defects of
CASZ1-depleted cells manifest themselves in vessel assembly,
we assessed sprouting using a sprouting angiogenesis assay
in which HUVEC-coated beads were placed in fibrin. Whereas
the control cells displayed elongated sprouts with multiple
branch points, similar to our findings in Xenopus, the CASZ1-
depleted HUVECs had strikingly few sprouts and branches
(Figure 3D). Live time-lapse imaging further showed that the
CASZ1-depleted cells extended out from beads to initiate sprout
formation but then abruptly detached, indicating that CASZ1 is
required for proper EC adhesion to promote angiogenic sprout-
ing (Movie S4).DeveIsolation of the Egfl7/miR-126 Locus by CASZ1
Chromatin Immunoprecipitation
To identify direct cardiac and endothelial transcriptional targets
of CASZ1, we generated a CASZ1-specific antibody and per-
formed a cloning chromatin immunoprecipitation (ChIP) screen
on dissected cardiovascular Xenopus tissue (stages 27–29,
i.e., the same time and tissue requiring CASZ1; Figure 4A). We
identified 110 putative transcriptional targets, including Egfl7,
an ECM protein that is specifically secreted by ECs and has
been shown to be associated with cellular processes similar to
those we observed for CASZ1 (i.e., EC adhesion and vessel
tubulogenesis; Figure 4B; Table S1; Nichol et al., 2010; Nikolic
et al., 2010; Parker et al., 2004).
Recently, studies in mouse and zebrafish identified the evolu-
tionarily conserved miR-126 contained within intron 7 of Egfl7
(Fish et al., 2008; Kuhnert et al., 2008; Wang et al., 2008). We
cloned Egfl7 and miR-126 from Xenopus and showed that
EGFL7 is 47% identical to human EGFL7 and 45% identical
to mouse EGFL7, whereas Xenopus miR-126 is completely
(100%) conserved between mouse and human (Fitch et al.,
2004; Figure S3A). Genome analysis and characterization of
Xenopus BACs corresponding to the Egfl7/miR-126 locus
confirmed that, like other model systems, miR-126 is located
within intron 7 of the Xenopus Egfl7 locus (Figure 4B).
Expression analysis revealed that Egfl7 is expressed in all
major vessels at all stages of vasculogenesis in Xenopus, as pre-
viously reported for zebrafish, mouse, and human (Figures 4C,
4E, 4G, and 4I; Fitch et al., 2004; Parker et al., 2004). Although
Egfl7 and miR-126 have been reported to be cotranscribed
and coexpressed in the vasculature, we found that Xenopus
miR-126 has an expression pattern distinct from that of Egfl7lopmental Cell 25, 132–143, April 29, 2013 ª2013 Elsevier Inc. 135
Figure 4. CASZ1 Directly Activates Egfl7
Transcription
(A) Illustration of cardiovascular-enriched region
dissected from X. tropicalis for ChIP.
(B) Genomic structure of the Xenopus Egfl7 locus,
denoting a CASZ1 ChIP fragment. White boxes:
exons; shaded boxes: miR-126 in intron 7 and
intronic region potentially containing CASZ1
element (±4 kb).
(C–J) In situ analysis of Egfl7 of stage 29–39 con-
trol and CASZ1-depleted embryos (lateral view
with anterior to the left). Note the downregulation
of Egfl7 in the vvn and isv of CASZ1-depleted
embryos.
(K) Relative mRNA expression of Egfl7, miR-126,
and Flk1 after infection of HUVECs with shCasz1.
mRNA levels relative to Rps29 ± SEM. ***p <
0.001; NS: not significant.
(L) Schematic demarcating Egfl7 genomic DNA
regions (in bp) tested for transcriptional activation.
E1 (55 to 1,614) within intron 3 but not E2
(1,773–3,840) resulted in increased luciferase (luc)
activity.
(M) Egfl7 genomic region E1 in the presence or
absence of Casz1. Bars represent fold increase in
activity relative to control ± SEM. Experiments
were repeated twice on independent batches of
embryos; **p < 0.01.
(N) Identification of a 90 bp region endoge-
nously bound by CASZ1 located within a non-
overlapping region of the E1.2 (113–227) PCR
amplicon.
See also Figure S3 and Table S1.
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CASZ1 Directly Regulates EGFL7/RhoAaswell as those reported in other species (Fish et al., 2008;Wang
et al., 2008). Most notably, miR-126 expression is initiated in ECs
at stage 32, slightly later than Egfl7 (stage 29), and we observed
strong expression of miR-126, but not Egfl7, in the developing
somites (Figures S3B–S3I). Taken together, these data show
that the sequence, genomic arrangement, and vascular expres-
sion of Egfl7 andmiR-126 are evolutionarily conserved; however,
in Xenopus, miR-126 has developed additional levels of regula-
tion distinct from Egfl7.
Consistent with Egfl7 being a direct target of CASZ1, analysis
in CASZ1-depleted embryos showed that Egfl7was initiated but
not maintained in vascular tissues at all stages analyzed (Figures
4D, 4F, 4H, and 4J). Consistently, Egfl7 levels were significantly
reduced (by 3-fold) in CASZ1-depleted HUVECs (Figure 4K). We
further observed a dramatic reduction in miR-126 (by 9-fold) in
CASZ1-depleted HUVECs (Figure 4K). These effects were spe-
cific, as the EC marker Flk1 was unaltered (Figure 4K). However,
we did not observe a reduction in miR-126 in CASZ1-depleted
Xenopus embryos at the mid- and late-tadpole stages (stages
32–39; Figures S3E, S3G, and S3I). Collectively, these studies
demonstrate that regulation of Egfl7 and miR-126 expression
in human ECs is dependent on CASZ1, whereas Xenopus miR-
126 appears to have evolved a CASZ1-independent mechanism
of regulation.
Egfl7 Is a Direct Transcriptional Target of CASZ1
To determine whether CASZ1 directly regulates Egfl7, we per-
formed in vivo transcriptional assays in which single copies of136 Developmental Cell 25, 132–143, April 29, 2013 ª2013 Elsevier Iintronic regions of Egfl7 corresponding to the putative CASZ1-
bound region (introns 2–5) were placed upstream of a basal
promoter driving luciferase activity. Of these intronic regions,
only the 50 half of intron 3 (E1) resulted in a dose-dependent,
reproducible increase in transcriptional activity in response to
CASZ1 (Figures 4L and 4M). To determine whether CASZ1 binds
endogenously to this element in vivo and to further refine the
region within E1, we performed ChIP of endogenous CASZ1
from early embryos (stage 32, a time point when CASZ1 is
required for Egfl7 expression). Results showed that CASZ1
binds to nucleotides 59–173 of intron 3 (E1.2), but not the most
50 end of E1 (E1.1; Figure 4N; data not shown). Thus, CASZ1
binds directly to the Egfl7 locus in vivo and can activate Egfl7
transcription through a regulatory element within intron 3 of the
Egfl7 locus.
EGFL7 Functions Downstream of CASZ1 to Control
Vascular Morphogenesis
To determine whether CASZ1 acts through EGFL7 to regulate
EC development, we depleted EGFL7 in embryos using a mor-
pholino that left miR-126 expression intact (Figures S4A–S4E).
Strikingly, EGFL7 depletion resulted in vascular phenotypes
that phenocopied CASZ1 depletion (Figures 5A–5H and S4F–
S4Q). As with CASZ1-depleted embryos, we found a reduction
in density of ECs within the vitelline vein network (stage 32; Fig-
ures 5A–5D, S4F, S4G, and S4J–S4M). Furthermore, although
blood vessels did form in EGFL7-depleted embryos, there was
significantly reduced branching and intersomitic vesselnc.
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CASZ1 Directly Regulates EGFL7/RhoAsprouting at later stages (Figures 5E–5H, S4H, S4I, and S4N–
S4Q). Quantification of vitelline vein networks at stage 36 re-
vealed results similar to those observed with CASZ1 depletion,
i.e., the total length of the vasculature and the number of branch
points and intersomitic vessels of EGFL7-depleted embryos was
significantly decreased compared with controls (Figure 5I).
Furthermore, like the CASZ1-depleted embryos, and in accor-
dance with reports of EGFL7 depletion in zebrafish (Parker
et al., 2004), lumens of posterior cardinal veins of EGFL7-
depleted embryos failed to form (Figures 5J–5M). Morpholinos
targeting the Dicer cleavage site of Xenopus pri-miR-126 had
no effect on Egfl7 expression (Figures S5A–S5E) and did not
result in gross defects in vessel morphology or patterning, in
accordance with reports in zebrafish (Figures S5F–S5U; Fish
et al., 2008). Consistently, the lumens of the posterior cardinal
veins of miR-126-depleted embryos were indistinguishable
from those of controls (Figures S5V–S5Y). Taken together, these
results imply that EGFL7 functions downstream of CASZ1 to
regulate angiogenesis and vascular remodeling.
Similar to our studies in Xenopus, time-lapse imaging of
HUVECs revealed that depletion of EGFL7 by shRNA (shEgfl7,
11-fold decrease in mRNA; Figure 5N) phenocopied CASZ1
depletion. Most notably, EGFL7-depleted cells showed adhe-
sion and proliferation defects similar to those observed in
CASZ1-depleted cells (Figure 5O; Movie S2), and also displayed
an elongated morphology similar to but not as extensive as that
observed in CASZ1-depleted cells. The sprouting angiogenesis
assay further demonstrated defects similar to those found in
CASZ1-depleted cells, i.e., the total length of sprouts and
number of branch points were significantly decreased in
EGFL7-depleted cells compared with controls (Figure 5P). Live
imaging showed that failure to sprout was due to the inability
of EGFL7-depleted cells to maintain adhesion (Movie S5). These
results were specific, since we observed a minimal effect on
expression of Casz1 or Flk1 (Figure 5N). Collectively, these
studies show that EGFL7 functions downstream of CASZ1 to
control vascular morphogenesis in Xenopus and humans. In
addition, miR-126 does not function downstream of CASZ1 in
Xenopus vascular development.
EGFL7 and miR-126 Function Downstream of CASZ1 to
Regulate Cell Adhesion and Shape
To test whether CASZ1 functions through Egfl7 or miR-126 to
regulate vascular development and morphogenesis in human
ECs, we assessed whether restoration of Egfl7 or miR-126 levels
rescues defects associated with CASZ1-depletion. Whereas
29% of cells infected with shCasz1 rounded up and detached,
compared with 3% of control cells, infection of CASZ1-depleted
cells with adenoviral constructs expressing either human Egfl7
(Ad-Egfl7) or miR-126 (Ad-miR-126) recovered proper adhesion,
as only 7.6% and 1%of cells detached, respectively (Figures 6A,
S6A, and S6B; Movie S3). However, restoration of Egfl7, but
not miR-126, partially rescued EC morphology associated with
CASZ1 depletion, as measured by the length-to-width ratio
(L:W; Figures 6B and S6C). Restoration of either Egfl7 or miR-
126 failed to rescue proliferation defects (data not shown). Taken
together, these studies demonstrate that CASZ1 acts to control
EC adhesion through direct transcriptional regulation of Egfl7
and miR-126. These data further indicate that EGFL7 and miR-Deve126 have distinct functions with regard to cell morphology, since
EGFL7, but not miR-126, can rescue cell-shape changes. They
also imply that CASZ1 control of G1/S progression occurs by
Egfl7- and miR-126-independent pathways.
CASZ1 and EGFL7 Regulate RhoA
Previous studies have provided evidence that two of the physio-
logical outputs of the CASZ1/EGFL7 pathway, cell adhesion
and morphology, are directly controlled by activation of Rho
GTPases. Specifically, RhoA is required for actomyosin-depen-
dent cell contractility and formation of focal adhesions (FAs; Bur-
ridge and Wennerberg, 2004; Katoh et al., 2011; Parsons et al.,
2010). To identify mechanisms that mediate the physiological
function of the CASZ1/EGFL7 pathway, we aimed to determine
the relationship between CASZ1/EGFL7 and RhoA. We found
that RhoA activity and levels were dramatically diminished in
CASZ1- and EGFL7-depleted cells, whereas the levels of other
Rho proteins, such as RhoC, were unaltered (Figures 6C, S6D,
and S6E). The decrease in RhoA protein occurred at the
transcriptional level, as RhoA (but not RhoC) mRNA levels
were markedly diminished in both CASZ1- and EGFL7-depleted
ECs (Figure 6D). However, RhoB levels were slightly increased,
possibly indicating a compensatory mechanism for loss of
RhoA (Figure 6D).
We reasoned that a reduction of RhoA expression in
CASZ1- and EGFL7-depleted cells would result in concomitantly
impaired downstream activity. Consistently, phosphorylation
of the regulatory subunit of myosin light chain (p-MLC) was
decreased in CASZ1-depleted cells (Figure S6F). To further
assess whether decreased RhoA activity directly plays a role in
the adhesion and cell-shape defects we observe in CASZ1-
depleted cells, we analyzed a panel of cytoskeletal and FA
markers. Control cells displayed discrete bundles of F-actin
stress fibers, as assayed by phalloidin staining, that contained
short or punctate bands of the FA markers vinculin and phos-
phorylated paxillin (Figure 6E, left panels). However, CASZ1
depletion mimicked treatment with the Rho kinase (ROCK) inhib-
itor Y-27632, resulting in diffuse actin networks devoid of stress
fibers and the failure of vinculin and phosphorylated paxillin to
properly localize to adhesion sites on the periphery of the cell
(Figure 6E,middle panels; Narumiya et al., 2000). This phenotype
was partially rescued by restoration of Egfl7 levels in CASZ1-
depleted cells (Figure 6E, right panels). Taken together, these
studies show that CASZ1 acts through the direct transcriptional
regulation of EGFL7 to control EC adhesion and shape via the
RhoA pathway.
DISCUSSION
In this work we demonstrate an essential and conserved role for
the CASZ1/EGFL7/RhoA pathway in vascular patterning. Collec-
tively, these data support a mechanism whereby CASZ1 directly
binds to andmaintains expression of Egfl7 in ECs. EGFL7 is then
localized extracellularly, where it modulates signals between
ECs and the underlying ECM. This in turn is responsible for the
transcriptional upregulation and activity of the RhoA GTPase,
which ultimately mediates EC contractility and adhesive proper-
ties to promote assembly, lumen formation, and functionality of
the vasculature (Figure 7).lopmental Cell 25, 132–143, April 29, 2013 ª2013 Elsevier Inc. 137
Figure 5. EGFL7 Depletion in Embryos and HUVECs Phenocopies CASZ1 Depletion
(A–H) In situ analysis with ECmarkerMsr of control and EGFL7-depleted embryos (stages 32–36, lateral viewwith anterior to left). Note the lack of branching in the
vvn at stage 32 (A and C: high magnification of the vvn in B and D) and stage 36 (E and G: high magnification of the vvn in F and H); isv sprouting is also impaired
(A, C, E, and G). n = 10 embryos/condition/stage, three independent experiments.
(I) Quantification of vascular defects in control and EGFL7-depleted embryos (stage 36) representing total vessel length, number of branch points within the vvn,
and number of isv/embryo. Data represent mean ± SEM (n = 7 control and 10 Egfl7 MO embryos). *p < 0.05, **p < 0.01, ****p < 0.0005.
(J–M) Histological analysis reveals lumenless pcv in stage 36 (K) and stage 39 (M) EGFL7-depleted embryos compared to control (J and L). Top: dorsal; bottom:
ventral; arrowheads correspond to pcv positions enlarged in lower panels (n = 3 embryos/condition/stage).
(N) mRNA expression of Egfl7, miR-126,Casz1, and Flk1 after infection of HUVECswith shEgfl7.Egfl7 is decreased 11-fold. mRNA levels relative toRps29 ± SEM.
***p < 0.001; NS, not significant.
(legend continued on next page)
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Figure 6. EGFL7 and miR-126 Play Distinct
Roles Downstream of CASZ1
(A) Quantification of cells coinfected with shCasz1
and Ad-Egfl7 or Ad-miR-126 that round up and
detach versus shCasz1 or control shRNA alone.
Data represent the mean ± SEM of two average
experiments conducted on independent batches
of shRNA-infected cells. n = 100 cells; **p < 0.01,
****p < 0.0005.
(B) Quantification of cell morphology as deter-
mined by measuring the L:W ratio. Morphology
was improved in cells coinfected with shCasz1
and Ad-Egfl7, but not in cells coinfected with
Ad-miR-126. Data represent the mean ± SEM
of three experiments conducted on independent
batches of shRNA-infected cells. n = 300–600
cells; **p < 0.01, ****p < 0.0005.
(C) RhoA protein expression in shRNA-infected
HUVECs. RhoA levels were markedly decreased
by depletion of CASZ1 and EGFL7. Graph shows
the densitometry of RhoA levels relative to
GAPDH.
(D) Relative RhoA, RhoB, and RhoC mRNA
expression after shRNA infection. mRNA levels
relative to Rps29 ± SEM. *p < 0.05, ***p < 0.001;
NS, not significant.
(E) Stress fibers and FAs disrupted in CASZ1-
depleted HUVECs resemble cells treated with
ROCK inhibitor Y-27632 (10 mM). Restoration of
Egfl7 in CASZ1-depleted cells rescues proper FA
localization. Phalloidin marks F-actin filaments
(green), and vinculin (red) and phosphorylated
paxillin (yellow) mark FAs.
See also Figure S6 and Movie S3.
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PromoteAssemblyofaWell-BranchedVascularNetwork
During embryogenesis, ECs assemble into cord-like structures
that undergo further remodeling to form the primary vascular
plexus. We have shown that CASZ1 acts through the direct tran-
scriptional regulation of Egfl7 to promote two critical processes
during this period of embryogenesis: sprouting angiogenesis
and lumen morphogenesis. The presence of thickened cords
lacking lumens in CASZ1-depleted embryos, together with the
observation that CASZ1-depleted ECs fail to sprout properly or(O) Quantification of cells that round up and detach during imaging. Data represent the mean ± SEM of two e
shRNA-infected cells. n = 100 cells; **p < 0.01.
(P) A sprouting angiogenesis assaywas performedwith control and EGFL7-depleted HUVECs. On day 6, cultu
DRAQ5 (blue). Graphs represent the mean ± SEM of total sprout length and number of branch points/bead (n
twice on independent batches of shRNA-infected cells. **p < 0.01, ***p < 0.001.
See also Figures S4 and S5 and Movies S2 and S5.
Developmental Cell 25, 132–1adhere to extracellular substrates,
strongly implies that CASZ1 functions
through the EGFL7/RhoA pathway to
maintain proper EC adhesion during
vessel assembly.
CASZ1 and RhoA
RhoA has been shown to be a central
component of pathways that facilitatevascular remodeling. In this regard, RhoA has been demon-
strated to be required for stress fiber formation, acting through
the actomyosin contractile machinery, and for FA formation
(Burridge and Wennerberg, 2004; Chrzanowska-Wodnicka and
Burridge, 1996; Katoh et al., 2011; Nobes and Hall, 1995). In
accordance with the notion that CASZ1 acts through RhoA to
promote proper EC adhesion, we find that depletion of CASZ1
phenocopies inhibition of RhoA and leads to a lack of discrete
stress fibers, decreased myosin II activity, and, strikingly, the
absence of FA markers at sites of substrate contact. Moreover,xperiments conducted on independent batches of
reswere fixed and stained for phalloidin (green) and
= 11 beads/condition). Experiments were repeated
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Figure 7. Model Describing CASZ1 Func-
tion in ECs
CASZ1 functions by binding to an intronic element
within the Egfl7 locus to activate proper levels of
Egfl7 in endothelial cells. EGFL7 is then secreted
to the ECM, where it likely binds cell-surface
receptors that signal downstream to activate
RhoA expression. Consequently, RhoA signaling
modulates endothelial cell behaviors, such as
adhesion and contractility, to promote vessel
assembly and morphogenesis.
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depleted background by restoration of Egfl7.
The role of RhoA in tubulogenesis has been controversial.
Although some reports have demonstrated that RhoA activity is
central for lumen formation, for example in the formation of the
mouse dorsal aorta (Strilic et al., 2009), other reports have shown
that in cultureRhoA is not required for lumen formation, but rather
for maintenance of patent vessels (Bayless and Davis, 2002).
However, the in vivo relevance of the latter observation has yet
to be determined, since the mechanism by which lumens arise
in 3D collagen culture differs significantly from that of cord hol-
lowing in vivo (Davis et al., 2007;Strilicet al., 2009). Paradoxically,
it was recently demonstrated that RhoA and myosin II activity
must be suppressed to promote lumen formation of mouse ves-
sels via negative regulation by Ras interacting protein 1 (RASIP1;
Xu et al., 2011). Collectively, these studies along with our present
findings imply that a precise level of RhoA activity is required for
lumen formation, with either too low or too high activity leading to
failure of the vascular cords to hollow and form lumens.
The finding that expression of RhoA protein and mRNA is
significantly diminished in CASZ1 and EGFL7-depleted HUVECs
indicates that transcriptional control of RhoA is impaired. Very
few studies to date have focused on how RhoA transcription is
controlled. Although EGFL7 has been shown to interact with lysyl
oxidases that are responsible for vascular elastogenesis, as well
as some Notch receptors on both ECs and neural stem cells, it is
still unclear how these interactions may be influencing RhoA
transcription or activity (Lelie`vre et al., 2008; Nichol et al.,
2010; Schmidt et al., 2009). However, our results would support
a mechanism by which CASZ1 modulates RhoA signaling
through EGFL7, as restoration of Egfl7 levels in CASZ1-depleted
cells rescues adhesion, proper FA marker localization, and
stress fiber formation. It was recently shown that RhoA is directly
activated by the Myc-Skp2-Miz1-p300 transcriptional complex
(Chan et al., 2010). Given the role of c-Myc in embryonic vascular
development and later angiogenic remodeling (Baudino et al.,
2002; Kokai et al., 2009; Rodrigues et al., 2008), it will be inter-
esting to investigate whether CASZ1 transcriptional regulation140 Developmental Cell 25, 132–143, April 29, 2013 ª2013 Elsevier Inc.of Egfl7 plays a direct role in Myc-medi-
ated transcriptional control of RhoA.
Transcriptional Regulation of Egfl7
and miR-126
Studies on Egfl7 and miR-126 have iden-
tified a 5.4 kb upstream sequence that is
sufficient to drive EC-specific expressionof a reporter gene in mouse, and mutation of two evolutionarily
conserved Ets binding sites within this element eliminated ex-
pression in culture (Wang et al., 2008). By showing that CASZ1
is endogenously bound to intron 3 of the Egfl7 locus in devel-
oping embryos and depletion of EGFL7 phenocopies CASZ1
depletion in embryos and HUVECs, we have demonstrated
that CASZ1 is required for expression of Egfl7. Consistently,
we noted that CASZ1 is not required for onset of Egfl7 expres-
sion in embryos but is necessary to maintain that expression.
Based on our studies, we favor amodel bywhich Ets factors acti-
vate Egfl7 via an upstream element, and CASZ1 binds to intron 3
and functions tomaintain Egfl7 levels. This model is complemen-
tary to findings regarding the role of Ets factors in regulating the
spatial pattern of Egfl7 in mouse (Wang et al., 2008).
Our finding that EGFL7 and miR-126 are both regulated in a
CASZ1-dependent manner in humans is congruent with reports
in mouse. However, despite the complete conservation of miR-
126 across species, we also demonstrate that miR-126 has
undergone an evolutionarily divergent and unique means of
regulation, as exemplified by our findings that Xenopus miR-
126 is expressed in domains mutually exclusive to Egfl7 (i.e.,
somites) and expression of Xenopus miR-126 in the vasculature
is CASZ1 independent. These observations are broadly consis-
tent with recent reports that miR-126 transcription can occur
independently of host gene transcription through differential
intronic promoters (Monteys et al., 2010).
CONCLUSIONS
The vascular systemarises via concerted efforts of individual ECs
to harness their unique behaviors to assemble into tubular struc-
tures. The molecular and cellular mechanisms by which the
vasculature arises are still unclear, but we have identified previ-
ously unknown roles for CASZ1 in regulating sprouting and
morphogenesis. Although the endothelium becomes stabilized
and quiescent after embryonic development, vessels remain
sensitive to changes in environment due to injury, inflammation,
or improper cardiac output, which makes them susceptible to
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CASZ1 has been linked to adult vascular diseases such as
hypertension (Takeuchi et al., 2010). Events resulting in vascular
dysfunction during this disease are associated with aberrant
ECM remodeling, proliferation, and adhesion, all of which we
have demonstrated to also be dysregulated upon depletion of
CASZ1 (Lemarie´ et al., 2010). Therefore, it will be intriguing to
examine the mechanisms by which CASZ1 itself is regulated,
and to identify additional transcriptional targets that could trigger
the development of innovative therapeutic strategies in cardio-
vascular disease.
EXPERIMENTAL PROCEDURES
Xenopus Embryo Collection and Morpholino Design
Xenopus embryos were prepared and collected as previously described
(Showell et al., 2006). Embryos were staged according to Nieuwkoop and
Faber (1967). Morpholino oligonucleotides (MOs) were obtained from Gene
Tools. Casz1-specific MOs were used as previously described (Christine and
Conlon, 2008). Egfl7-specific MOs were designed against the acceptor region
of X. laevis exon 6, and miR-126-specific MOs were designed against the
guide dicer region of X. laevis (Supplemental Experimental Procedures).
In Situ Hybridization
Whole-mount in situ analysis was carried out as previously described (Harland,
1991) using probes of Casz1 (Christine and Conlon, 2008), Msr (Devic et al.,
1996), Ami (Inui and Asashima, 2006), Erg (cloned from stage 39 X. laevis com-
plementary DNA [cDNA]), Egfl7 (cloned from stage 33–38 X. tropicalis cDNA),
and EphrinB2 (cloned from stage 39 X. laevis cDNA). miR-126 locked nucleic
acid probes were obtained from Exiqon (38523-05) and hybridization was per-
formed according to the manufacturer’s instructions at 51C.
ChIP
Four hundred cardiovascular-enriched regions were dissected from stage 29
X. tropicalis embryos and processed for ChIP as previously described (Wein-
mann and Farnham, 2002; Taranova et al., 2006) with the following exceptions:
(1) sonication was carried out with a Branson Digital Sonifier at 20% amplitude
(2.5 cycles, 30 s [1 s on/0.5 s off]) to yield 4 kb DNA fragments, (2) affinity-
purified rabbit anti-CASZ1 polyclonal antibody (generated in house) was
added and incubated overnight at 4C, and (3) DNA was digested with NlaIII
(NEB) and ligated into SphI-digested (NEB) pUC19 using a DNA ligation kit
(Stratagene). Ligated DNA was transformed into NEB10b electrocompetent
cells. Transformants were selected by blue/white screening and cultured,
and isolated plasmids were sequenced. CASZ1 target DNA sequences were
assessed by BLAT analysis using the UCSC X. tropicalis Genome Browser
(http://genome.ucsc.edu, August 2005 assembly). DNA scaffold location
coordinates were imported into the annotated Joint Genome Institute v4.1
database (http://genome.jgi-psf.org/Xentr4/Xentr4.home.html). Validation of
targets by ChIP PCR was performed as above with the following exceptions:
(1)Thirty stage 32 X. tropicalis embryos were collected and processed, and
(2) samples were sonicated at 20% amplitude (five cycles, 30 s [1 s on/0.5 s
off]) to generate 300 bp DNA fragments.
In Vivo Transcriptional Assays
Egfl7 intronic regions (introns 2, 3, 4, and 5) were subcloned into pGL3-
Promoter firefly luciferase vector (Promega). X. laevis embryos were injected
at the one-cell stage with 300 pg reporter plasmid and 10 pg Renilla reporter
plasmid in the presence or absence of CASZ1 mRNA. Injected embryos
were cultured until stage 11.5. Ten injected embryos were lysed in 50 ml
Passive Lysis Buffer (Promega) in triplicate. Then 20 ml of cleared lysates
was assayed using the Dual-Luciferase Reporter Assay System (Promega).
Cell Culture
Pooled populations of HUVECs (Lonza) were maintained in Complete EBM-2
(Lonza) containing 10% fetal bovine serum (FBS), 100 U/mL penicillin and
streptomycin, and used between passages 1 and 6. hCASZ1 was immunopre-Devecipitated from HUVECs using polyclonal rabbit anti-human CASZ1 (LifeSpan
Biosciences) and probed by western blot with the same antibody.
shRNA
shRNA viral constructs specific to human Casz1 and Egfl7were obtained from
the Open Biosystems TRC1 shRNA library. Casz1, Egfl7, and control scram-
bled sequence (Addgene) shRNA lentiviral particles were prepared by the
UNC Lentiviral Core Facility. Then 40%–50% confluent HUVECs were infected
with 13 106 IU lentivirus combinedwith 10 mg/mL polybrene (Sigma) for 7.5 hr.
Infected cells were placed under 1.5 mg/mL puromycin selection for 3 days and
processed for further analysis.
Live Time-Lapse Imaging
Cells seeded on uncoated or fibronectin-coated (10 mg/mL) 12-well dishes or
embedded in fibrin gel were imaged over 24 hr using an Olympus IX70 inverted
microscope encased in Plexiglas housing to control the internal environment
(37C, 5% CO2, and relative humidity of 60%). Images were collected with
the use of Volocity 5.4.1 software.
Immunofluorescence
Cells seeded in chamber slides (BD Falcon) were fixed with cold methanol/
acetone, blocked, and incubated with pH3 (Millipore) or cleaved caspase-3
(Cell Signaling) overnight. Cells were incubated with rabbit anti-Cy3 (Sigma),
stained with DAPI, and mounted (DakoCytomation). For cytoskeletal staining,
cells were serum starved (EBM-2 + 0.75% FBS) overnight and half of the cells
were treated with 10 mM Y-27632 (Sigma). The cells were fixed in 4% parafor-
maldehyde, permeabilized with 0.1% Triton X-100, and incubated overnight
with anti-vinculin (Sigma) and anti-phospho-paxillin (pY118; Invitrogen). The
cells were incubated with fluorescent secondary antibodies, stained with
FITC-conjugated phalloidin (Invitrogen) and DAPI, mounted, and imaged
(Zeiss 710 or 700 microscope).
Sprouting Angiogenesis Assay
Sprouting assays were performed as previously described (Nakatsu et al.,
2003; Sweet et al., 2012). Cells were stained with phalloidin (FITC) to visualize
actin and with DRAQ5 to mark EC nuclei, and imaged (Olympus FLV500 in-
verted confocal microscope, 203 objective). The assays were used to mea-
sure the total length of protruding sprouts and the number of branch points.
Western Blotting
Western blots were performed with 50 mg protein using RhoA (Santa Cruz),
p-MLC 2 (Ser 19; Cell Signaling), and RhoC (K-12; Santa Cruz).
Statistical Analysis
Data are expressed as means ± SEM as indicated. Statistical analysis was
done by Student’s t test and p < 0.05 was considered significant.
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The GenBank accession number for Xenopus laevis miR-126 reported in this
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